Method of reversing carboplatin resistance by inhibition of HGFIN
US8383806B2 · kind B2 · utility
22Cited by
0References
1Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 13, 2011 |
| Grant date | Feb 26, 2013 |
| Priority date | — |
| Expiry date | Apr 13, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.